Eli Lilly strikes $2.75 billion deal with AI drug developer Insilico Medicine
Eli Lilly has agreed to license drug candidates from generative AI drug developer Insilico Medicine, with the deal potentially worth $2.75 billion including milestone payments. Insilico Medicine will receive $115 million upfront, plus development, regulatory, and commercial milestone payments, along with tiered royalties on future sales.
Under the agreement, Lilly gains exclusive rights to develop, manufacture, and commercialize preclinical oral drug candidates from Insilico Medicine for selected disease areas. Financial Times reported separately that Lilly will acquire exclusive rights to a GLP-1 drug for diabetes.
Why pharmaceutical companies are adopting AI for drug development
Drug manufacturers increasingly rely on AI for Healthcare to accelerate research and development. Modeling tools and automated labs promise efficiency gains across drug pipelines and reduce timelines for bringing treatments to market.
The U.S. Food and Drug Administration has signaled support for AI-driven development methods, particularly those that reduce animal testing. This regulatory backing removes a major barrier to adoption and encourages pharmaceutical companies to invest in AI capabilities or partner with specialized developers.
The deal's significance for the industry
The agreement reflects a broader trend: major pharmaceutical companies lack the internal AI expertise to build these systems themselves and are turning to specialized firms instead. Insilico Medicine's partnership with one of the world's largest drugmakers validates the commercial viability of AI-generated drug candidates.
Insilico Medicine is listed on the Hong Kong Stock Exchange under ticker 3696.HK.
Your membership also unlocks:
